Tumefactive fibroinflammatory lesion successfully treated with Rituximab

Jessica L. Bishop, Locke Johnson Bryan, Natasha Marie Savage, J. Kenneth Byrd

Research output: Contribution to journalArticle

Abstract

Skull base pseudotumors, or tumefactive fibroinflammatory lesions (TFIL), are tumors characterized by local destruction with benign histopathology. Treatment includes surgery and steroids with varying degrees of symptom relief. A 45-year-old female presented with right otorrhea and middle ear effusion, which progressed to CN V3 pain/numbness, trismus, headache, and autophony. MRI showed a diffuse infiltrating mass in the right infratemporal region involving the trigeminal ganglion. Biopsy revealed benign fibromuscular and adipose tissue with lymphoplasmacytic infiltrate, giving a diagnosis of TFIL. Resection would be very difficult given tumor location. Initial treatment included an extended course of steroids without response, and interval disease progression. Two courses of rituximab 375 mg/m2 weekly × 4 given 3 months apart were then completed with excellent tolerance. With sixteen months following induction, the patient reports minimal symptoms with radiographic findings confirming continued disease regression. Rituximab is a potential treatment option for patients with TFIL without response to steroids.

Original languageEnglish (US)
Pages (from-to)138-141
Number of pages4
JournalIntractable and Rare Diseases Research
Volume8
Issue number2
DOIs
StatePublished - Jan 1 2019

Fingerprint

Steroids
Trismus
Trigeminal Ganglion
Otitis Media with Effusion
Hypesthesia
Skull Base
Headache
Disease Progression
Adipose Tissue
Neoplasms
Therapeutics
Biopsy
Pain
Rituximab

Keywords

  • Immunomodulators
  • Inflammatory pseudotumors
  • Pseudotumor
  • Rituximab
  • Tumefactive fibroinflammatory lesion

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Tumefactive fibroinflammatory lesion successfully treated with Rituximab. / Bishop, Jessica L.; Bryan, Locke Johnson; Savage, Natasha Marie; Byrd, J. Kenneth.

In: Intractable and Rare Diseases Research, Vol. 8, No. 2, 01.01.2019, p. 138-141.

Research output: Contribution to journalArticle

@article{0de5f31b682c4c4a8d241d97ca9cf5bb,
title = "Tumefactive fibroinflammatory lesion successfully treated with Rituximab",
abstract = "Skull base pseudotumors, or tumefactive fibroinflammatory lesions (TFIL), are tumors characterized by local destruction with benign histopathology. Treatment includes surgery and steroids with varying degrees of symptom relief. A 45-year-old female presented with right otorrhea and middle ear effusion, which progressed to CN V3 pain/numbness, trismus, headache, and autophony. MRI showed a diffuse infiltrating mass in the right infratemporal region involving the trigeminal ganglion. Biopsy revealed benign fibromuscular and adipose tissue with lymphoplasmacytic infiltrate, giving a diagnosis of TFIL. Resection would be very difficult given tumor location. Initial treatment included an extended course of steroids without response, and interval disease progression. Two courses of rituximab 375 mg/m2 weekly × 4 given 3 months apart were then completed with excellent tolerance. With sixteen months following induction, the patient reports minimal symptoms with radiographic findings confirming continued disease regression. Rituximab is a potential treatment option for patients with TFIL without response to steroids.",
keywords = "Immunomodulators, Inflammatory pseudotumors, Pseudotumor, Rituximab, Tumefactive fibroinflammatory lesion",
author = "Bishop, {Jessica L.} and Bryan, {Locke Johnson} and Savage, {Natasha Marie} and Byrd, {J. Kenneth}",
year = "2019",
month = "1",
day = "1",
doi = "10.5582/irdr.2019.01061",
language = "English (US)",
volume = "8",
pages = "138--141",
journal = "Intractable and Rare Diseases Research",
issn = "2186-3644",
publisher = "International Advancement Center for Medicine & Health Research Co., Ltd. (IACMHR Co., Ltd.)",
number = "2",

}

TY - JOUR

T1 - Tumefactive fibroinflammatory lesion successfully treated with Rituximab

AU - Bishop, Jessica L.

AU - Bryan, Locke Johnson

AU - Savage, Natasha Marie

AU - Byrd, J. Kenneth

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Skull base pseudotumors, or tumefactive fibroinflammatory lesions (TFIL), are tumors characterized by local destruction with benign histopathology. Treatment includes surgery and steroids with varying degrees of symptom relief. A 45-year-old female presented with right otorrhea and middle ear effusion, which progressed to CN V3 pain/numbness, trismus, headache, and autophony. MRI showed a diffuse infiltrating mass in the right infratemporal region involving the trigeminal ganglion. Biopsy revealed benign fibromuscular and adipose tissue with lymphoplasmacytic infiltrate, giving a diagnosis of TFIL. Resection would be very difficult given tumor location. Initial treatment included an extended course of steroids without response, and interval disease progression. Two courses of rituximab 375 mg/m2 weekly × 4 given 3 months apart were then completed with excellent tolerance. With sixteen months following induction, the patient reports minimal symptoms with radiographic findings confirming continued disease regression. Rituximab is a potential treatment option for patients with TFIL without response to steroids.

AB - Skull base pseudotumors, or tumefactive fibroinflammatory lesions (TFIL), are tumors characterized by local destruction with benign histopathology. Treatment includes surgery and steroids with varying degrees of symptom relief. A 45-year-old female presented with right otorrhea and middle ear effusion, which progressed to CN V3 pain/numbness, trismus, headache, and autophony. MRI showed a diffuse infiltrating mass in the right infratemporal region involving the trigeminal ganglion. Biopsy revealed benign fibromuscular and adipose tissue with lymphoplasmacytic infiltrate, giving a diagnosis of TFIL. Resection would be very difficult given tumor location. Initial treatment included an extended course of steroids without response, and interval disease progression. Two courses of rituximab 375 mg/m2 weekly × 4 given 3 months apart were then completed with excellent tolerance. With sixteen months following induction, the patient reports minimal symptoms with radiographic findings confirming continued disease regression. Rituximab is a potential treatment option for patients with TFIL without response to steroids.

KW - Immunomodulators

KW - Inflammatory pseudotumors

KW - Pseudotumor

KW - Rituximab

KW - Tumefactive fibroinflammatory lesion

UR - http://www.scopus.com/inward/record.url?scp=85067495208&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85067495208&partnerID=8YFLogxK

U2 - 10.5582/irdr.2019.01061

DO - 10.5582/irdr.2019.01061

M3 - Article

VL - 8

SP - 138

EP - 141

JO - Intractable and Rare Diseases Research

JF - Intractable and Rare Diseases Research

SN - 2186-3644

IS - 2

ER -